Vita Life Sciences Limited (ASX:VLS)
Australia · Delayed Price · Currency is AUD 2.440
0.00 (0.00%)
Jul 30, 2026, 4:10 PM AEST
Vita Life Sciences Income Statement
Financials in millions AUD. Fiscal year is January - December.
Millions AUD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 93.27 | 79.51 | 73.43 | 66.89 | 57.1 | |
Revenue Growth | 17.31% | 8.28% | 9.78% | 17.14% | 22.85% |
Cost of Revenue | 36.23 | 32.26 | 31.05 | 27.15 | 22.29 |
Gross Profit | 57.04 | 47.24 | 42.38 | 39.74 | 34.81 |
Selling, General & Admin | 42.38 | 35.19 | 30.17 | 28.7 | 23.54 |
Other Operating Expenses | 0.59 | 0.4 | 0.34 | 0.31 | 0.26 |
Operating Expenses | 42.97 | 35.59 | 30.51 | 29.01 | 23.79 |
Operating Income | 14.07 | 11.66 | 11.88 | 10.73 | 11.02 |
Interest Expense | -0.11 | -0.05 | -0.06 | - | -0.06 |
Interest & Investment Income | 0.99 | 1.04 | 0.56 | 0.14 | 0.14 |
Currency Exchange Gain (Loss) | -0.29 | 0.07 | -0.21 | -0.12 | 0.01 |
Other Non Operating Income (Expenses) | -0.22 | -0.08 | -0.05 | -0 | 0.11 |
EBT Excluding Unusual Items | 14.43 | 12.64 | 12.12 | 10.75 | 11.21 |
Gain (Loss) on Sale of Assets | - | - | - | - | -0 |
Asset Writedown | - | - | 0.34 | -0.01 | -0.01 |
Pretax Income | 14.43 | 12.64 | 12.45 | 10.74 | 11.2 |
Income Tax Expense | 4 | 3.86 | 3.37 | 3.4 | 2.95 |
Earnings From Continuing Operations | 10.43 | 8.78 | 9.08 | 7.34 | 8.25 |
Minority Interest in Earnings | 0.01 | 0.01 | 0 | -0.26 | 0.05 |
Net Income | 10.44 | 8.78 | 9.08 | 7.08 | 8.29 |
Net Income to Common | 10.44 | 8.78 | 9.08 | 7.08 | 8.29 |
Net Income Growth | 18.80% | -3.26% | 28.18% | -14.57% | 36.07% |
Shares Outstanding (Basic) | 56 | 56 | 54 | 53 | 53 |
Shares Outstanding (Diluted) | 57 | 56 | 55 | 54 | 53 |
Shares Change | 2.27% | 1.70% | 1.30% | 1.64% | 0.97% |
EPS (Basic) | 0.19 | 0.16 | 0.17 | 0.13 | 0.16 |
EPS (Diluted) | 0.18 | 0.16 | 0.17 | 0.13 | 0.16 |
EPS Growth | 16.21% | -4.88% | 26.52% | -15.95% | 34.80% |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 15.86 | 5.96 | 12.32 | 2.64 | 5.73 |
Free Cash Flow Per Share | 0.28 | 0.11 | 0.23 | 0.05 | 0.11 |
Dividend Per Share | 0.140 | 0.100 | 0.090 | 0.060 | 0.058 |
Dividend Growth | 40.00% | 11.11% | 50.00% | 4.35% | 35.29% |
Gross Margin | 61.15% | 59.42% | 57.72% | 59.41% | 60.96% |
Operating Margin | 15.08% | 14.66% | 16.17% | 16.04% | 19.29% |
Profit Margin | 11.19% | 11.05% | 12.37% | 10.59% | 14.52% |
Free Cash Flow Margin | 17.00% | 7.49% | 16.78% | 3.94% | 10.04% |
EBITDA | 14.55 | 12.01 | 12.12 | 10.98 | 11.25 |
EBITDA Margin | 15.60% | 15.11% | 16.51% | 16.42% | 19.71% |
D&A For EBITDA | 0.49 | 0.36 | 0.25 | 0.25 | 0.24 |
EBIT | 14.07 | 11.66 | 11.88 | 10.73 | 11.02 |
EBIT Margin | 15.08% | 14.66% | 16.17% | 16.04% | 19.29% |
Effective Tax Rate | 27.75% | 30.55% | 27.09% | 31.64% | 26.37% |